This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Magnesium Sulphate in Perinatal Asphyxia (Magsulf)

This study has been completed.
Information provided by (Responsible Party):
Dr.Mushtaq, Sheri Kashmir Institute of Medical Sciences Identifier:
First received: November 2, 2007
Last updated: October 12, 2016
Last verified: November 2013
Magnesium sulphate has been shown to be neuroprotective. The investigators hypothesize that magnesium sulphate infusion given to babies with perinatal asphyxia should improve outcome in the immediate neonatal period.

Condition Intervention Phase
Perinatal Asphyxia , Moderate to Severe HIE Drug: Magnesium sulphate Drug: Normal saline Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Magnesium Sulphate in Perinatal Asphyxia: A Randomized Placebo Controlled Trial.

Resource links provided by NLM:

Further study details as provided by Dr.Mushtaq, Sheri Kashmir Institute of Medical Sciences:

Primary Outcome Measures:
  • good short term out come [ Time Frame: at discharge ]
    Death and or abnormal neurological outcome at discharge

Secondary Outcome Measures:
  • abnormal neurological examination and abnormal CT Head [ Time Frame: at discharge ]

Enrollment: 40
Study Start Date: September 2004
Study Completion Date: August 2006
Primary Completion Date: August 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Magnesium sulphate, neurological outcome
Magnesium sulphate 250mg/kg after every 24 hours starting within 6 hours from birth
Drug: Magnesium sulphate
250 mg/kg/dose in 1 ml normal saline
Placebo Comparator: Placebo
Placebo every 24 hours for 3 doses starting from 6 hours after birth
Drug: Normal saline
1 ml/kg/dose

Detailed Description:
Magnesium sulphate has a neuroprotective potential as has been shown by many studied in pregnant ladies with eclampsia where it helped neonates also and in mothers with preterm labour where the incidence of cerebral palsy was less. We designed a randomised controlled trial on 40 neonates with severe perinatal asphyxia to see whether it helps in the short term outcome of these neonates.

Ages Eligible for Study:   up to 6 Hours   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Babies eligible for the study were:

    1. Term or post term
    2. Less than 6 hours of age and had
    3. severe perinatal asphyxia as manifested by any three of the following criteria.

      • History of fetal distress (late deceleration, Loss of beat to beat variability, fetal bradycardia, meconium stained amniotic fluid)
      • Need for immediate neonatal ventilation with bag and mask or through endotracheal intubation for 2 minutes or more after delivery
      • A 5-minute Apgar score of < 6
      • Base deficit 15 mEq/L in cord blood or admission arterial or cord blood pH 4.Moderate to severe encephalopathy

Exclusion Criteria:

  • Patients with severe IUGR
  • Any condition unrelated to asphyxia
  • Maternal prenatal magnesium administration
  • Metabolic disorder
  • Chromosomal anomalies; and
  • Congenital malformations were excluded from the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00553072

Sheri-Kashmir Institute of Medical Scienceds
Srinagar, Jammu and Kashmir, India
Sponsors and Collaborators
Sheri Kashmir Institute of Medical Sciences
Principal Investigator: Dr.Mushtaq A Bhat, M.D. SKIMS
Study Chair: Dr.Javeed I Bhat, M.D. SKIMS
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Dr.Mushtaq, Professsor, Sheri Kashmir Institute of Medical Sciences Identifier: NCT00553072     History of Changes
Other Study ID Numbers: SKIMS-001
Study First Received: November 2, 2007
Last Updated: October 12, 2016

Keywords provided by Dr.Mushtaq, Sheri Kashmir Institute of Medical Sciences:
magnesium sulphate

Additional relevant MeSH terms:
Asphyxia Neonatorum
Pathologic Processes
Wounds and Injuries
Infant, Newborn, Diseases
Magnesium Sulfate
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Depressants
Anti-Arrhythmia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Tocolytic Agents
Reproductive Control Agents processed this record on June 23, 2017